1 Multiple effects of TNFa inhibitors on the development of the adaptive immune response 2 after SARS-CoV-2 vaccination 3 Ulf Martin Geisen^{1*}, Ruben Rose^{2*}, Franziska Neumann³, Maria Ciripoi¹, Lena Vullriede¹, 4 Hayley M Reid¹, Dennis Kristopher Berner¹, Federico Bertoglio⁴, Paula Hoff⁵, Michael Hust⁴, 5 Ann Carolin Longardt, Thomas Lorentz³, Gabriela Rios Martini^{7,9}, Carina Saggau⁷, Jan Henrik 6 Schirmer¹, Maren Schubert⁴, Melike Sümbül⁹, Florian Tran^{8,10}, Mathias Voß², Rainald 7 Zeuner¹, Peter J Morrison⁹, Petra Bacher^{7,8}, Helmut Fickenscher², Sascha Gerdes⁹, Matthias 8 Peipp¹¹, Stefan Schreiber^{8,10}, Andi Krumbholz^{2,3‡}, Bimba Franziska Hoyer^{1‡} 9 10 11 1 Medical Department I, Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein 12 Campus Kiel, Kiel, Germany 13 2 Institute for Infection Medicine, Christian-Albrecht University of Kiel and University Medical Center 14 Schleswig-Holstein, Campus Kiel, Kiel, Germany 15 3 Labor Dr. Krause und Kollegen MVZ GmbH, Kiel, Germany 16 4 Institute of Biochemistry, Biotechnology, and Bioinformatics, Department of Biotechnology, Technische 17 Universität Braunschweig, Braunschweig, Germany. 18 5 Department of Rheumatology, Endokrinologikum-Gruppe, Berlin, Germany 19 6 Department of Pediatrics, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Germany 20 7 Institute of Immunology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Germany 21 8 Institute of Clinical Molecular Biology, Christian-Albrecht University of Kiel, Kiel, Germany 22 9 Department for Dermatology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Germany 23 10 Department for Internal Medicine I, University Medical Center Schleswig-Holstein Campus Kiel 24 11 Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, University Medical Center 25 Schleswig-Holstein Campus Kiel, Kiel, Germany 26 27 * ‡These authors contributed equally 28 29 Abstract 30 **Objectives:** 31 The humoral immune response to SARS-CoV-2 vaccination in patients with chronic

- inflammatory disease (CID) declines more rapidly with TNFα inhibition. Furthermore, the
- efficacy of current vaccines against Omicron variants of concern (VOC) including BA.2 is
- 34 limited. Alterations within immune cell populations, changes in IgG affinity and the ability to
- neutralise a pre-VOC strain and the BA.2 virus were investigated in these at-risk patients.
 Methods:
- 37 Serum levels of anti-SARS-CoV-2 IgG, IgG avidity and neutralising antibodies (NA) were
- 38 determined in anti-TNF α patients (n=10) and controls (n=24 healthy individuals; n=12
- 39 patients under other disease-modifying anti-rheumatic drugs, oDMARD) before and after the
- 40 second and third vaccination by ELISA, immunoblot and live virus neutralisation assay. SARS-
- 41 CoV-2-specific B- and T cell subsets were analysed by multicolour flow cytometry.
- 42 Results:
- 43 IgG avidity and anti-pre-VOC NA titres decreased faster in anti-TNFα recipients than in
- 44 controls 6 months after the second vaccination (healthy individuals: avidity: $p \le 0.0001$; NA:
- 45 p=0.0347; oDMARDs: avidity: p=0.0012; NA: p=0.0293). Total plasma cell counts were
- 46 increased in anti-TNF α patients (Healthy individuals: p=0.0344; oDMARDs: p=0.0254),
- 47 whereas absolute numbers of SARS-CoV-2-specific cells were comparable 7 days after
- 48 vaccination. These patients had lower BA.2 NA titres compared to both other groups, even
- 49 after the third vaccination.
- 50 Conclusions:

51 We show a reduced SARS-CoV-2 neutralising capacity in patients under TNFα blockade. In

52 this cohort, the plasma cell response appears to be less specific and show stronger

53 bystander activation. While these effects were observable after the first two vaccinations

and with older VOC, the differences in responses to BA.2 were magnified.

55

What is already known on this topic – Patients with chronic inflammatory diseases treated
 with TNFα inhibitors show a greater decrease in SARS-CoV-2 IgG 6 months after the second
 vaccination than patients taking oDMARDs and healthy individuals.

59

What this study adds – Antibodies from patients taking TNFα blockers have a lower SARS CoV-2 neutralising capacity and maturity. Plasma cells from these patients exhibit less
 specific immune reaction. SARS-CoV-2-specific T cells are less activated. Neutralisation
 against BA.2 is drastically reduced even after the third vaccination.

64

How this study might affect research, practice or policy – This study emphasizes the need
to protect vulnerable groups such as patients using TNF inhibitors. They could benefit from
Omicron-adapted vaccination, but most likely they need to be protected by additional
means other than vaccination.

69

70 Keywords: COVID19, Tumor Necrosis Factor Inhibitors, Vaccination, Autoimmune Diseases

71

72 Word Count: 3091 (max 3500)

73 Abstract: 250

74

75 Introduction

The current SARS-CoV-2 pandemic poses a particular challenge for patients with chronic inflammatory disease (CID) receiving immunosuppressive therapies. For example, certain immunosuppressive therapies/pharmaceuticals (e.g., B cell depleting therapies, antimetabolites such as methotrexate, high-dose corticosteroids) are known to interfere with SARS-CoV-2 vaccine efficacy.(1) However, long-term data from this population on immune response to the vaccines are lacking.

82

83 Previously, we found that CID patients under tumour necrosis factor alpha (TNF α) inhibiting 84 therapy initially showed a largely normal, albeit slightly delayed, immune response to SARS-85 CoV-2 mRNA vaccines which was followed by a rapid decline of anti-spike (S) and virus-86 neutralising antibody (NA) levels compared to patients receiving other disease modifying 87 anti-rheumatic drugs (oDMARDs) and healthy controls.(2) While the difference in anti-S 88 antibody levels was marginal at day 7 and absent at day 14 after the second vaccination, 89 these patients had significantly lower anti-S lgG levels six months after vaccination. 90 Moreover, the neutralising capacity of serum in CID patients treated with TNF α inhibitors 91 was dramatically reduced at the sixth month after vaccination, as shown by a surrogate 92 neutralisation assay.(3) This impairment of adaptive immunity during anti-TNF α treatment 93 has also been confirmed by other research groups, including live virus neutralisation data 94 using the Delta variant of concern (VOC) as antigen.(4, 5) Compared with healthy controls, 95 anti-S IgA levels were decreased in CID patients at all time points after vaccination, 96 suggesting impaired mucosal immunity.(3) It remains unclear what biological mechanisms 97 lead to this impaired antibody response and whether these differences indicate generally 98 lower immunity after vaccination compared with controls. The relationship between B cells

and T cells during SARS-CoV-2 vaccination is not fully understood, as humoral and T cell
 immunity appear to depend on B cell counts before vaccination.(6) In addition, data from
 immunocompromised kidney transplant patients show that T cell activity after vaccination
 correlates with the magnitude of the antibody response,(7) while high T cell activity has
 been observed in B cell depleted patients after immunisation.(8)

104

105 Sera from vaccinated healthy individuals show only limited neutralisation capacity against 106 Omicron (B.1.1.529) VOC.(9, 10) This variant, consisting of several sublineages, including 107 BA.1 and BA.2, is considered a separate serotype that is antigenically distinct from the 108 original Wuhan strain (designated here as wild-type, wt, or pre-VOC) and other VOCs.(11) 109 The marked immune escape of BA.1 and BA.2 and the importance of booster vaccination for 110 the development of NA against both sublineages have recently been demonstrated, (10) 111 especially the need of mRNA boost immunisations for persons vaccinated with inactivated 112 viruses.(12)

113

Only limited data are available on the persistence of NA against various SARS-CoV-2 lineages
(including Omicron) in CID patients receiving anti-TNFα therapy after double vaccination.
Virtually no data are available on the development of binding strength (avidity) of vaccineinduced IgG antibodies, which is considered an expression of their maturity and optimal
epitope binding (13) (14), for this group of patients, nor are there any data on the
development of cellular immunity.

120

121 The aim of this study is to clarify the influence of immunosuppressive therapy on the 122 development of adaptive immunity after SARS-CoV-2 vaccination. To this end, the quality 123 and quantity of SARS-CoV-2-specific B cells, plasmablasts, T cells, and antibodies were 124 measured at different time points after the second vaccination. We report differential 125 development of anti-BA.2 NAs after a third dose of vaccine.

126

127 Methods

128 Patient recruitment and biosampling

The study was approved by the ethics committee of the Christian-Albrecht University Kiel 129 (D409/21). There was no patient and public involvement in conducting the study. 130 Recruitment of patients and repetitive biosampling was performed as previously 131 132 described.(2) The SAVE-CID cohort consists of 47 healthcare workers and other risk groups 133 who received their first SARS-CoV-2 vaccination in January 2021 followed by a second 134 vaccination 5 or 3 weeks later. Samples taken 7 days after the third vaccination were also 135 examined in 12 patients. All patients received BNT162b2 (Comirnaty, Pfizer/BioNTech) or 136 mRNA-1273 (Spikevax, Moderna). Biosampling and data acquisition as well as data on 137 antibody concentration, surrogate neutralisation data and clinical characterisation of this 138 cohort has already been published.(2, 3) The patient groups were age and gender matched 139 resulting in mean ages of 43 (TNF α inhibitor, median: 42.5), 41.25 (Healthy Control, median: 140 39) and 41.63 (oDMARDs, median: 46).

141

142 Production of SARS-CoV-2 S1 proteins

143 S1 domain of the S protein(GenBank: MN908947) with different tags were baculovirus-free 144 produced in High Five cells (Thermo Fisher Scientific) by transient transfection as previously 145 described. (15, 16) Protein purification was performed depending 1 or 5 mL column on Äkta 146 go (Cytiva), Äkta Pure (Cytiva), or Profina System (BIO-RAD). HiTrap Fibro PrismA (Cytiva) 147 was used as resins for Protein A purification (Fc-tagged proteins). For His-tag purification of 148 insect cell supernatant HisTrapexcel column (Cytiva) was used. All purifications were 149 performed according to the manufacturer's manual. S1-HIS was further purified by SEC by a 150 16/600 Superdex 200 kDa pg (Cytiva).

151

152 Isolation of peripheral blood mononuclear cells (PBMC) and Flow Cytometry

153 PBMCs from EDTA blood were isolated within three hours of blood collection by density 154 gradient centrifugation (Biocoll, Bio&SELL GmbH, Feucht, Germany). Afterwards, 4x10⁶ 155 PBMCs were incubated with his-tagged S1 protein (own protein or Euroimmun, Lübeck, 156 Germany).(9) PBMCs were then stained with pre-mixed antibodies (CD19-PerCP-Vio-700 157 (REA657, Miltenyi Biotec, Bergisch-Gladbach, Germany), CD20-PE-Cio770 (REA780, Miltenyi 158 Biotec), CD3-Pacific Blue (OKT3, Biolegend, San Diego, USA), CD14 Pacific Blue (M5E2, 159 Biolegend), CD27-APC (M-T271, Biolegend), anti-HIS-PE (JO95-G46, Biolegend), Biolegend), 160 HLA-DR-VioGreen (REA805, Miltenyi Biotec), CD138-BV605 MI15, Biolegend)) and analysed 161 using a MacsQuant 16 Cytometer (Miltenyi Biotec, Bergisch-Gladbach, Germany). Secondary 162 staining using AF-700 coupled S1-fc protein were used as gating and staining control to 163 exclude false positive events (see figure S1 and S2 for more information). For the calculation 164 of immune cells per blood volume, 50µL of whole blood was stained, (CD3-Pacific Blue 165 (Biolegend), CD14-FITC (REA599, Miltenyi Biotec), CD4-PE (Vit4, Miltenyi Biotec), CD19-166 PerCP-Vio700 and CD45-APC-Vio770 (H130, Biolegend)), lysed, (Red blood lysis, BD) and 167 measured on a MACSQuant 16 (Miltenyi Biotec). The cell counts per 50µL blood for each 168 sample were used to calculate all other cell counts from the PBMC staining. Staining and 169 measurement were performed in PBS containing 1% BSA, 0.5% EDTA and 0.1% sodium azide.

170

171 Measurement of Antibody Secreting Cells by Three-Colour Fluorospot

PBMCs were isolated as described above and different T cell numbers were incubated for
three hours in a 96-well 0.45µM PVDF Immobilon-FL membrane plate (Merck Millipore,
Burlington, MS, USA) which was pre-coated with SARS-CoV-2 protein or FAB2-fragments

against Immunoglobulins A, M (both Southern Biotech, Birmingham, USA), G (Jackson Immunoresearch, Cambridge, UK) and blocked with 15%. FCS in PBS. After 3 washing steps with deionised water, the wells were stained using IgA-FITC, IgG-FC-AF555 and IgM-AF647 (all Southern Biotech). Measurement was performed on a Bioreader 6000Fb equipped with Eazyreader software (Bio-SYS, Karben, Germany)

180

181 Antigen-reactive T cell enrichment (ARTE)

The ARTE was performed as previously described (17-20). In brief, 0.5-1x10⁷ PBMCs were 182 stimulated for 7 hours with 0.5 µg/peptide/ml SARS-CoV-2 S peptide pool (JPT, Berlin, 183 184 Germany) in presence of 1 μ g/ml CD40 and 1 μ g/ml CD28 pure antibody (both Miltenyi 185 Biotec, Bergisch Gladbach, Germany). 1 μ g/ml Brefeldin A (Sigma Aldrich) was added for the 186 last two hours. Cells were magnetically isolated using the CD154 MicroBead Kit (Miltenyi Biotec). After surface staining with CD4-APC-Vio770 (M-T466), CD8-VioGreen (REA734), 187 CD14-VioGreen (REA599), CD20-VioGreen (LT20) (all Miltenyi Biotec), CD45RA-PE-Cy5 188 (HI100), PD-1 Brilliant Violet 605 (EH12.2H7), CCR7-Brilliant-Violet-785 (G043H7) (all 189 190 BioLegend), cells were fixed, permeabilized and stained intracellular with CD154-FITC 191 (REA238), IL-21-PE (REA1039) (both Miltenyi Biotec), IFN-γ-PerCP-Cy5.5 (4S.B3), TNFα-192 Brilliant-Violet-650 (MAb11), IL-10-PE-Dazzle (JES3-9D7) (all BioLegend), IL-2-BV711 193 (5344.111), Ki-67-Alexa Fluor 700 (B56) (both BD Biosciences). Viobility 405/520 Fixable Dye 194 (Miltenyi Biotec) was used to exclude dead cells. Data were acquired on a LSR Fortessa (BD 195 Bioscience, San Jose, CA, USA). CD154⁺ background cells enriched from the non-stimulated 196 control were subtracted and frequencies of antigen-specific T cells were determined based 197 on CD154⁺ T cells after enrichment, normalised to the total number of CD4⁺ T cells applied 198 on the column.

199

200 Binding strength (avidity) of SARS-CoV-2 IgG antibodies

201 The IgG avidity was assessed with the *recom*Line SARS-CoV-2 IgG assay on a Dynablot Plus 202 system together with a BLOTrix reader and the recomScan software (all from Mikrogen 203 GmbH, Neuried, Germany) as reported previously.(21) This immunoblot consists of a 204 nitrocellulose strip separately carrying recombinant nucleocapsid protein (NP) and the S1-205 and RBD-subunits of the S protein. Binding of IgG to these SARS-CoV-2 antigens in presence 206 or absence of avidity reagent was automatically measured and assigned to four categories: 207 no avidity detectable (=0), low avidity (=1), intermediate avidity (=2) and high (=3) 208 avidity.(22)

209

210 Measurement of neutralising antibodies against a pre-VOC strain and a BA.2 strain

211 Sera were tested in triplicate using a Vero cell-based live virus neutralisation test (cVNT) in 212 96-well format under biosafety level 3 conditions, as previously reported.(10, 22) In brief, 213 sera were diluted 1:10 to 1:1280 in cell culture medium free of fetal calf serum. As antigens 214 for the cVNT, we used either 50 plaque-forming units per well of a B.1 strain (pre-VOC of 215 2020) or an Omicron BA.2 strain, which we had previously isolated (23) and characterised by 216 whole-genome sequencing.(10, 23) After four (pre-VOC) or six (BA.2) days of incubation, 217 cells were fixed by addition of paraformaldehyde and stained with an aqueous crystal violet 218 methanol solution. Serum dilutions (titres) > 1:10 that prevented the formation of a 219 cytopathic effect in ≥ 2 wells were considered to contain neutralising antibodies (NA); if no

exact titre could be given, the geometric mean of the two adjacent titres was calculated.(10,22)

- 222
- 223 Data analysis and statistics

Flow cytometry data was analysed using FlowJo v10 (BD Bioscience). Statistical analyses and graphs were prepared using RStudio (version 2022.02.0+443) and Prism 8 (GraphPad Software, LLC). For analysis of differences between the groups, Kruskal-Wallis Test and nonparametric pairwise comparisons were performed.

- 228
- 229 Results
- 230

Anti-S-IgG-antibody concentrations, IgG avidity and neutralisation efficacy decrease 6 months after vaccination

233 Under TNF α inhibitor therapy, anti-S-IgG levels after the second immunisation were 234 significantly lower than in patients receiving oDMARDs or in healthy controls (figure 1a). 235 None of the subjects showed anti-NP IgG reactivity, making infection breakthrough unlikely 236 (data not shown). The IgG avidity and neutralisation capacity against the pre-VOC strain 237 were high in all tested groups 14 days after second vaccination (avidity: median avidity index 238 (MAI) = 3; NA: geometric mean titres (GMT)=1:98-1:234)(figure 1B, C). Six months after 239 second vaccination, IgG avidity and pre-VOC NA titres significantly decreased in TNFa-240 inhibitor treated vaccinees (n=8; avidity: MAI=1.25; NA: GMT=1:2) compared to patients 241 receiving oDMARDs (n=7; avidity: MAI=3, p=0.0012; NA: GMT=1:38, p=0.0293) and healthy 242 controls (n=12; avidity: MAI=3, $p \le 0.0001$; NA: GMT=1:25, p=0.0347) (figure 1A). Relative to 243 the pre-VOC strain, anti-BA.2 NA titres were significantly lower than against the pre-VOC 244 strain in all three groups at day 14 after the second vaccination (GMT=1:2-1:4 vs. GMT=1:98-245 1:234; p=0.0001-0.0072) and were not detected after six months (GMT<1:10, figure 1D). At 7 246 days after the third vaccination, anti-BA.2 NAs were detectable in all subjects except 247 patients taking a TNF α blocker (n=4 per group; GMT=1:62-1:95 vs. GMT=1:3). At this time 248 point, IgG avidity was high in all subjects except one patient receiving anti-TNF α treatment.

249

250 Plasma cell populations are altered in patients using TNFα blockers

Patients under TNF α inhibiting therapy showed higher numbers of plasmablasts in the peripheral blood 7 days after the second vaccination (median: 9.153cells/µL) compared to patients receiving oDMARDs (median: 2.205cells/µL, p=0.0254) (figure 2A) and healthy controls (2.657 cells/µL, p=0.0344).

255 When comparing SARS-CoV-2 specific plasma cells at the same timepoint, no differences 256 between patients on TNF α blockade (median 0.295 cells/ μ L) and healthy controls (median 257 0.333 cells/ μ L) were detected, while patients treated with oDMARDs other than TNF α 258 inhibitors had significantly lower cell numbers compared to healthy controls (median: 0.204 259 cells/ μ L; p=0.0015) (figure 2B).

260 Anti-TNFα treated patients generally displayed more peripheral blood IgA plasma cells than

261 controls and patients receiving oDMARDs (figure 2C). This trend became significant on day

262 14 after vaccination for patients under oDMARDs (median 0.404 cells/ μ L) and TNF α blockers 263 (median 1.818 cells/ μ L; p=0.0397).

264 With regards to SARS-CoV-2-specific IgA-plasma cells, counts were lower in the anti-TNF α 265 group on day 7 after the second vaccination (median: 0.016 cells/µL) compared to healthy 266 controls (median: 0.052 cells/µL; p=0.0203) and patients treated with oDMARDs 267 (median:0.035 cells/µL; p=0.0299) (figure 1D).

Overall numbers of mature circulating CD138⁺ plasma cells were higher in patients on TNF α 268 269 blockade (median: 0.101 cells/ μ L) than in healthy controls (median: 0.031 cells/ μ L; 270 p=0.0055) and patients treated with oDMARDs (median: 0.019 cells/ μ L; p=0.0015) on day 14 271 after second vaccination (figure 2E). Differences at time points between the first and the 272 second vaccination were not significant. We were not able to detect differences in the 273 number of SARS-CoV-2 specific plasma cells. However, on day 7 after second vaccination, 274 healthy controls had higher numbers of circulating CD138⁺ plasma cells in the peripheral 275 blood (median: 0.004 cells/ μ L) than patients using TNF α inhibitors (median: 0.002 cells/ μ L; 276 p=0.0055) or receiving oDMARDs (median: 0.001 cells/ μ L; p=0.0026) (figure 2F).

277

Anti-TNFα treatment does not change the number of SARS-CoV-2 specific antibody secreting cells

280 Relative to the other two sample groups, anti-TNF α patients showed a pronounced increase 281 in SARS-CoV-2 specific antibody secreting cells (ASCs) of the IgM isotype at day 7 post 282 second vaccination, while total numbers of ASC of all other isotypes remained comparable 283 between groups (figure 3A). Analysing spot size in our Fluorospot assays as a surrogate for 284 the amount of secreted antibody per cell, both patient groups generally displayed larger 285 spot sizes suggesting increased antibody secretion per ASC (figure 3B). These differences 286 were not significant except for IgA (p=0.0026 for TNF vs. Healthy Control and p=0.001 for 287 oDMARDs vs. Healthy Control). No differences were detected between the two patient 288 groups. The number of ASCs correlated well with SARS-CoV-2 serum IgG levels and the 289 number of SARS-CoV-2 positive plasmablasts at the same timepoint (figure 3C-D). No 290 antigen specific plasma cells were detected in the blood of any participant before the first 291 vaccination (data not shown).

292

300

293 SARS-CoV-2 specific T cells show signs of delayed activation

SARS-CoV-2 S-specific CD4+ T cells could be detected at similar frequencies in all groups
after second vaccination (figure 4A). We also observed no differences in cytokine production
(TNFα, IFNγ, IL-2, IL-21 or IL-10) by the S-specific T cells between TNFα patients, oDMARDs
and controls (figure 4B). In contrast, TNFα patients showed significantly lower expression of
PD-1 and a trend towards increased levels of Ki-67, suggesting a delayed or still ongoing
activation of these cells (figure 4C).

301 Discussion

To our knowledge, we present the first such comprehensive data on the longitudinal course
 of adaptive immunity in CID patients vaccinated against SARS-CoV-2 undergoing TNFα
 blockade.

These patients show an altered immune response after vaccination relative to oDMARD patients and healthy controls in the absence of breakthrough infections, suggesting that such individuals should be monitored more closely for loss of SARS-CoV-2 immunity.

308 Most strikingly, anti-TNF α patients exhibited a stronger decrease in IgG avidity and 309 neutralisation capacity 6 months after vaccination and did not acquire NAs against BA.2 after 310 a third vaccination. To our knowledge this is the first report concerning the long-term 311 neutralisation efficacy against BA.2 VOC within this patient population after vaccination. 312 While the neutralisation efficiency against the initial pre-VOC wt strain was marginally lower 313 in anti-TNF α -treated patients 14 days after second vaccination compared to the other 314 groups, this difference was more pronounced against the BA.2 strain where overall low 315 neutralisation was detected. Six months after second vaccination, BA.2 NAs were not

detected in any of the three study groups, suggesting that the S antigen of this VOC is
relevantly different from that of wt and derived VOCs, consistent with recent studies.(10, 24)
The loss of IgG avidity was unexpected as anti-TNFα patients displayed similarly high IgG
avidity as the other groups at day 14 post second vaccination. Conversely, other studies have
shown, that the avidity of anti- SARS-CoV-2 IgG increases during the subsequent months
after vaccination.(13) This decline of avidity several months after the vaccination anti-TNFα
patients has not been previously reported.

323 In addition, various changes in the plasmablast compartment of patients were observed in 324 response to vaccination. Hence, patients using TNF inhibitors had higher numbers of plasma 325 cells after the first vaccination (d0.2) relative to the two other groups. These differences 326 increase after the second vaccination, suggesting a stronger immune reaction. The 327 frequency of SARS-CoV-2 specific plasma cells within this population was decreased in the 328 patient groups compared to controls. The absolute number of SARS-CoV-2 specific 329 plasmablasts however was comparable to the other groups, suggesting that the immune 330 reaction triggered under TNFα therapy is more unspecific.

331

332 Higher numbers of mature CD138⁺ plasmablasts were detected within the non-SARS-CoV2-333 specific plasma cells from anti-TNF α patients. These cells are usually found in the bone 334 marrow.(25) The difference in maturity between S-specific and non-specific plasma cells may 335 represent a reduced capacity to form long-lived specific plasma cells in anti-TNF α patients. 336 However, assessment of these cells in the peripheral blood might not reflect their state in 337 the bone marrow and our measurements after second vaccination may be too early for the 338 detection of long-lived SARS-CoV-2-specific plasma cells. We also noted that a large 339 proportion of these CD138⁺ plasma cells expressed HLA-DR (Figure S4). These phenotypically 340 mature (CD138⁺) and antigen presenting plasmablasts (HLA-DR) were also described in 341 patients with severe COVID19 (26) their function remains unclear.

342

Interestingly, although broadly homogeneous, there were two outliers in our cohort of antiTNFα patients. One patient had consistently high antibody concentrations, high IgG avidity
and NAs at 6 months. The other patient had consistently low values for all three parameters.
These outliers show the importance of individual monitoring of patients at risk of reduced
immunity after vaccination.

348

349 Our data demonstrate that TNF α inhibitors affect the adaptive immune response after SARS-350 CoV-2 vaccination. This is reflected in the development of IgG avidity, virus neutralising 351 capacity, plasma cell and T cell populations. We recommend regular measurement of anti-352 SARS-CoV-2 IgG levels and especially NA titres in these patients, as this group may benefit 353 from early booster vaccination. To our knowledge, current commercial anti-SARS-CoV-2 354 antibody tests are based on antigens still derived from the wild type. However, if available, 355 assays adapted to the currently circulating variants should preferably be used. In addition, 356 the development of variant-specific surrogate neutralisation tests would be desirable, as 357 these, unlike live virus neutralisation assays, can also be used in routine laboratories. CID 358 patients on TNF α inhibitor therapy who have no, or low detectable antibody levels should be 359 particularly protected from COVID-19. Following SARS-CoV-2 infection, these patients might 360 require close monitoring and early administration of monoclonal antibodies that also cover 361 currently circulating VOC. In addition, we recommend the use of a vaccine adapted to the 362 current VOC as soon as it becomes available. 363

364 The mechanisms leading to decreased antibody response during immunosuppressive

- treatment need to be further explored to improve vaccine regimens for these high-riskpatients.
- 367
- 368
- 369
- 370 Contributors

Study design: UMG, FT, MP, SS, AK, HF, BFH. Sample collection: DKB,ACL, JHS, MS, FT, RZ, SG.
Experiments and data analysis: UMG, RR, FN, MC, LV, HMR, PB, FB, MH, MV, AK, HF and BFH.
Tables and figures: UMG, RR and BFH. Data interpretation: UMG, RR, PB, AK, HF and BFH.
Writing of the manuscript: UMG, PH, PJM, AK and BFH. Critical proof reading of the
manuscript: all authors.

376

377 Acknowledgement

378

We thank Meike Zahnen (UKSH, Rheumatology), Ina Martens (UKSH, Rheumatology), Sina
Müller (Labor Dr. Krause und Kollegen) and Carina Bäumler (Labor Dr. Krause und Kollegen)
for excellent technical and organisational assistance.

- We acknowledge the support of the European Union for the ATAC ("antibody therapy against corona". Horizon2020 number 101003650) consortium.
- The authors thank Mikrogen GmbH, Neuried, Germany, for providing free or discounted kitsfor IgG avidity detection.
- 386
- 387 Funding

Cross-funded by Bundesministerium für Bildung und Forschung (Grant GAIN_01GM1910D), DIO002/CoVispecT research grant from the Land Schleswig-Holstein, the German Network University Medicine NUM NaFoUniMedCovid19" (FKZ: 01KX2021), project COVIM and by the Deutsche Forschungs-Gemeinschaft Cluster of Excellence Precision Medicine in Chronic Inflammation and Transregio 130. BFH, PH and SS received funding from Pfizer and other companies.

- 394
- 395 Competing Interests
- 396 None declared
- 397
- 398
- 399 400

- References
- Boekel L, Steenhuis M, Hooijberg F, Besten YR, van Kempen ZLE, Kummer LY, et al.
 Antibody development after COVID-19 vaccination in patients with autoimmune diseases in
 the Netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatol.
 2021;3(11):e778-e88.
- 405 2. Geisen UM, Berner DK, Tran F, Sümbül M, Vullriede L, Ciripoi M, et al.
- Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic
 inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Annals
 of the rheumatic diseases. 2021:annrheumdis-2021-220272.

Geisen UM, Sümbül M, Tran F, Berner DK, Reid HM, Vullriede L, et al. Humoral
protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies. RMD
open. 2021;7(3).

412 4. Chen RE, Gorman MJ, Zhu DY, Carreño JM, Yuan D, VanBlargan LA, et al. Reduced 413 antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated 414 individuals receiving tumor necrosis factor- α inhibitors. Med (N Y). 2021;2(12):1327-41.e4. 415 5. Farroni C, Picchianti-Diamanti A, Aiello A, Nicastri E, Laganà B, Agrati C, et al. Kinetics 416 of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination 417 in Patients With Rheumatoid Arthritis. Frontiers in immunology. 2022;13:846753. 418 6. Stefanski AL, Rincon-Arevalo H, Schrezenmeier E, Karberg K, Szelinski F, Ritter J, et al. 419 B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination 420 Among Patients Treated With Rituximab. Arthritis & rheumatology (Hoboken, NJ). 2021. 421 7. Schrezenmeier E, Rincon-Arevalo H, Stefanski AL, Potekhin A, Straub-Hohenbleicher 422 H, Choi M, et al. B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney 423 Transplant Recipients. J Am Soc Nephrol. 2021;32(12):3027-33. 424 8. Fabris M, De Marchi G, Domenis R, Caponnetto F, Guella S, Dal Secco C, et al. High T-425 cell response rate after COVID-19 vaccination in belimumab and rituximab recipients. 426 Journal of autoimmunity. 2022;129:102827. 427 9. Schubert M, Bertoglio F, Steinke S, Heine PA, Ynga-Durand MA, Maass H, et al. 428 Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding 429 to the RBD of SARS-CoV-2 Omicron variant. BMC Med. 2022;20(1):102. 430 Rose R, Neumann F, Müller S, Bäumler C, Schäfer M, Schön F, et al. Delta or Omicron 10. 431 BA.1/2-neutralizing antibody levels and T-cell reactivity after triple-vaccination or infection. 432 Allergy. 2022. 433 11. Simon-Loriere E, Schwartz O. Towards SARS-CoV-2 serotypes? Nature Reviews 434 Microbiology. 2022;20(4):187-8. 435 Zuo F, Abolhassani H, Du L, Piralla A, Bertoglio F, de Campos-Mata L, et al. 12. 436 Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits 437 strong immunity against SARS-CoV-2 Omicron variant. Nature communications. 438 2022;13(1):2670. 439 13. Bauer G. High avidity of vaccine-induced immunoglobulin G against SARS-CoV-2: 440 potential relevance for protective humoral immunity. Exploration of Immunology. 441 2022;2(2):113-56. 442 Bauer G. The potential significance of high avidity immunoglobulin G (IgG) for 14. 443 protective immunity towards SARS-CoV-2. International Journal of Infectious Diseases. 444 2021;106:61-4. 445 15. Korn J, Schackermann D, Kirmann T, Bertoglio F, Steinke S, Heisig J, et al. Baculovirus-446 free insect cell expression system for high yield antibody and antigen production. Scientific 447 reports. 2020;10(1):21393. 448 Bertoglio F, Meier D, Langreder N, Steinke S, Rand U, Simonelli L, et al. SARS-CoV-2 16. 449 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors 450 binding at RBD-ACE2 interface. Nature communications. 2021;12(1):1577. 451 17. Bacher P, Heinrich F, Stervbo U, Nienen M, Vahldieck M, Iwert C, et al. Regulatory T 452 Cell Specificity Directs Tolerance versus Allergy against Aeroantigens in Humans. Cell. 453 2016;167(4):1067-78.e16. 454 Bacher P, Hohnstein T, Beerbaum E, Röcker M, Blango MG, Kaufmann S, et al. Human 18. 455 Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against Candida albicans. 456 Cell. 2019;176(6):1340-55.e15. 457 Bacher P, Rosati E, Esser D, Martini GR, Saggau C, Schiminsky E, et al. Low-Avidity 19. 458 CD4(+) T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe 459 COVID-19. Immunity. 2020;53(6):1258-71.e5.

Bacher P, Schink C, Teutschbein J, Kniemeyer O, Assenmacher M, Brakhage AA, et al.
Antigen-reactive T cell enrichment for direct, high-resolution analysis of the human naive
and memory Th cell repertoire. Journal of immunology (Baltimore, Md : 1950).

463 2013;190(8):3967-76.

464 21. Neumann F, Rose R, Römpke J, Grobe O, Lorentz T, Fickenscher H, et al. Development

of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of
 Concern or Vaccination. Vaccines. 2021;9(7):700.

467 22. Rose R, Neumann F, Grobe O, Lorentz T, Fickenscher H, Krumbholz A. Humoral
468 immune response after different SARS-CoV-2 vaccination regimens. BMC Medicine.
469 2022;20(1):31.

470 23. Strömer A, Rose R, Schäfer M, Schön F, Vollersen A, Lorentz T, et al. Performance of a
471 Point-of-Care Test for the Rapid Detection of SARS-CoV-2 Antigen. Microorganisms.
472 2021;9(1):58.

472 24. Rössler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 Omicron Variant
474 Neutralization in Serum from Vaccinated and Convalescent Persons. N Engl J Med.

475 2022;386(7):698-700.

476 25. Khodadadi L, Cheng Q, Radbruch A, Hiepe F. The Maintenance of Memory Plasma477 Cells. Frontiers in immunology. 2019;10:721.

478 26. Bernardes JP, Mishra N, Tran F, Bahmer T, Best L, Blase JI, et al. Longitudinal multi-479 omics analyses identify responses of megakaryocytes, erythroid cells and plasmablasts as 480 hallmarks of severe COVID-19 trajectories. Immunity.

482

483 Figure legends

484

485 Figure 1: A Patients using TNF α blockers show reduced antibody serum levels, avidiy and 486 neutralisation at different timepoints. Serum IgG antibody against SARS-CoV-2 Spike 1 487 subunit at different timepoints as single values per patient. Lines indicate the median. **B** IgG 488 avidity indices of anti-S IgGs of SARS-CoV-2. C Neutralising antibodies against the wild-type 489 (wt) and D BA.2 variant of SARS-CoV-2 at 14 days and six months after the second 490 vaccination. For BA.2 and IgG avidity, a time point 7 days after the third vaccination was 491 added (n=4 per group); values are given as individual values and median. Statistical 492 differences: Kruskal-Wallis test with Dunn's post hoc test, significant differences are 493 indicated as *P<0.05, **P<0.01, ***P<0.001, ****P<0.001

494

495 Figure 2: Patients using TNF α blockers show higher numbers of overall plasmablasts and 496 SARS-CoV-2 specific plasmablasts 7 days after the second vaccination. A Flow cytometry 497 analysis of B cell subsets at different timepoints after a vaccination against SARS-CoV-2. 498 Values are shown as cells per microlitre of blood. Boxes and whiskers indicate median and 499 95%CI. **B** SARS-CoV-2 specific plasmablasts. IgA^{*} plasmablasts **C** and SARS-CoV-2 specific **D** 500 IgA^{+} positive plasmablasts. E and F: CD138⁺ unspecific and SARS-CoV-2 specific plasmablasts 501 which resemble mature plasma cells. If not indicated otherwise, cell counts per microlitre 502 blood are shown as single values with median. Statistical differences: Kruskal-Wallis test with 503 Dunn's post hoc test, significant differences are indicated as *P<0.05, **P<0.01, ****P<0.0001 504

505

Figure 3: Antibody secreting cells (ASC) measured in 3-colour-Fluorospot 7 days after the
 second vaccination. See figure S3 for representative image. A Number of total and SARS CoV-2 specific ASCs per μL blood. B Spot size distribution. Single points resemble the mean

509 spot size per spot of one donor. Correlation (Pearson) of the number of SARS-Cov-2 specific

510 ASCs **C** against SARS-CoV-2 specific plasma blasts in flow cytometry and **D** against SARS-CoV-

511 2 serum IgG. Statistical differences: Kruskal-Wallis test with Dunn's post hoc test, significant

- 512 differences are indicated as *P<0.05, ***P<0.001
- 513

Figure 4: SARS-CoV-2 specific memory T cells in patients receiving TNF α blockers show a delayed activation status. Antigen-reactive T cell enrichment was performed two months after the second vaccination. A Frequencies of spike-reactive CD154+ memory cells within CD4+ T cells. B Percentage of cytokine production within spike-reactive CD154+ memory cells. C Percentage of PD-1 and Ki-67 positive cells within CD154+ memory cells. Each dot represents one donor, lines indicate mean values. Statistical differences: Kruskal-Wallis test with Dunn's post hoc test, significant differences are indicated as **P<0.01

521 522









в

